Materias dentro de su búsqueda.
Mostrando 1,541 - 1,560 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.55s Limitar resultados
  1. 1541
    “…Two systems of antibody-drug conjugates (ADCs), noncleavable H32-DM1 and cleavable H32-VCMMAE, were developed by using different linkers and drugs attached to the anti-HER2 antibody H32, which is capable of cell internalization. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells
  2. 1542
    Publicado 2019
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
  3. 1543
    por Leyton, Jeffrey V.
    Publicado 2020
    “…Therapeutic anti-HER2 antibodies and antibody–drug conjugates (ADCs) have undoubtedly benefitted patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2
  4. 1544
    “…Overexpression of the HER2 receptor occurs in approximately 20% of breast cancer patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes
  5. 1545
    “…Efficient electrocatalyst toward hydrogen evolution/oxidation reactions (HER/HOR) and oxygen reduction reaction (ORR) is desirable for water splitting, fuel cells, etc. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Anion-Modulated Platinum for High-Performance Multifunctional Electrocatalysis toward HER, HOR, and ORR
  6. 1546
    por Park, Jeong A., Cheung, Nai-Kong V.
    Publicado 2020
    “…T cells armed with anti-GD2-BsAb (GD2-EATs) or anti-HER2-BsAb (HER2-EATs) showed significant anti-tumor activities as well. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
  7. 1547
    por Guan, Jingyuan, Zhang, Mei
    Publicado 2021
    “…In the present review, anthracycline-free oncological therapy regimens for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and the associated cardiovascular toxicity are discussed, as well as some monitoring strategies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer
  8. 1548
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma
  9. 1549
    “…We envision this effective procedure for obtaining large amounts of cancer-specific EVs will accelerate discovery of EV-associated RNA biomarkers for cancers including HER2+ breast cancer.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Towards establishing extracellular vesicle-associated RNAs as biomarkers for HER2+ breast cancer
  10. 1550
    “…Evidence on preferences of Canadian patients and physicians for treatments for advanced breast cancer is limited. (2) Methods: Patients’ and physicians’ preferences for treatments for HR+/HER2−, pre-/peri-menopausal advanced breast cancer were assessed by an online discrete choice experiment (DCE). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
  11. 1551
    “…PURPOSE: The addition of trastuzumab to adjuvant chemotherapy has improved the outcome of human epidermal growth-factor receptor 2 (HER2)-positive breast cancer. Uncertainty remains about the optimal timing of trastuzumab treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
  12. 1552
    “…Combined targeting of HER2 and ER, however, has yielded disappointing results in the clinical setting. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
  13. 1553
    por Cheong, E. Von, Ho, Gwo Fuang
    Publicado 2021
    “…The development of resistance to trastuzumab in HER2‐positive gastroesophageal cancer remains a problem. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
  14. 1554
    “…RESULTS: all cases regardless of grades of endometrioid carcinoma showed negative expression of HER2 (score 0). CONCLUSION: there was no significant HER2 expression in endometrioid carcinoma. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A study of HER2 expression in endometrial carcinoma: a single centre experience
  15. 1555
    “…Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
  16. 1556
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Our science and the Covid-19 pandemic—Katalin Karikó’s research idea and her perseverance
  17. 1557
    por Zhao, Hengqiang, Gong, Yiping
    Publicado 2021
    “…In addition, ER+PR+HER2+ showed similar OS and better BCSS compared with ER+PR+HER2- after PSM. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
  18. 1558
    por Lüftner, Diana, Peipp, Matthias
    Publicado 2021
    “…Despite therapeutic gains in the treatment of HER2-positive (HER2: human epidermal growth factor receptor 2) advanced/metastatic breast cancer, there remains an urgent need for more effective treatment options. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
  19. 1559
    “…Thus, we showed that the smallest HER2-recognizing polypeptide affibody Z(HER2:342) is more effective in terms of specificity and selectivity in nanoparticle-mediated cell labeling.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative Evaluation of Engineered Polypeptide Scaffolds in HER2-Targeting Magnetic Nanocarrier Delivery
  20. 1560
    “…SIMPLE SUMMARY: Development of brain metastases is an important event for patients with breast cancer, and it affects both their survival and their quality of life. Patients with HER2-positive breast cancer are more commonly affected by brain metastases compared to patients with HER2-negative/hormone receptor-positive breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
Herramientas de búsqueda: RSS